UPC_APP_9038/2025

METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY

Prozessuale & UnteranträgeStreithilfeMilan CDApplication Rop313—

Übersicht Entscheidungen Zitate Dokumente Zeitverlauf

Parteien

Kläger

Zentiva, k.s.
ZENTIVA PORTUGAL, LDA

Vertreter: Marc Lauzeral

Beklagte

Accord Healthcare B.V.
Accord Healthcare S.L.U.
ACCORD HEALTHCARE LIMITED,
Novartis AG

Vertreter: Gregory Bacon (Bristows (Ireland) LLP); Rutger Kleemans (Freshfields); Daniela Ampollin (Trevisan & Cuonzo); Allard van Duijn (Freshfields)

Richter

Patente

EP 2 501 384

CPC-Codes: A61P11/06, A61P37/06, A61P43/00, A61P17/00, A61P9/12, A61K31/506, A61P17/06, A61P19/02, A61P25/28, A61P35/00, A61K31/505, C07D239/69…

Sektor: Organic Chemistry

Ausgang

Abgewiesen

Eingereicht: —

Erste Entscheidung: 21. März 2025

Sprache: —

The Milan Central Division dismissed Zentiva K.S. and Zentiva Portugal's application to intervene under Rule 313 RoP in infringement proceedings between Accord Healthcare and Novartis concerning EP 2 501 384. The court held that parallelism between cases or the potential impact of one judgment on another does not establish the legal interest required for intervention, and that the intervening party's requested remedies must be non-contradictory to those of the supported party.